In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprim
about
The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitroPharmacokinetics and tissue penetration of enoxacinUptake and intracellular activity of sparfloxacin in human polymorphonuclear leukocytes and tissue culture cellsComparative double-blind study of 200- and 400-mg enoxacin given orally in the treatment of acute uncomplicated urethral gonorrhea in malesChemotherapeuticsInfluence of medium and method on the in vitro susceptibility of Pseudomonas aeruginosa and other bacteria to ciprofloxacin and enoxacinIntravenous enoxacin for the treatment of acute pyelonephritis: pharmacokinetic and clinical study.Activity of E-3846, a new fluoroquinolone, in vitro and in experimental cystitis and pyelonephritis in rats.Development of resistance to nalidixic acid and the fluoroquinolones after the introduction of norfloxacin and ofloxacinComparative effects of enoxacin and norfloxacin on human colonic microflora.Penetration of pefloxacin into cerebrospinal fluid of patients with meningitisIn vitro and in vivo antibacterial activities of the fluoroquinolone WIN 49375 (amifloxacin).Activities of new quinoline derivatives against genital pathogens.In vitro activities of enoxacin and 17 other antimicrobial agents against multiply resistant, gram-negative bacteria.Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes.Enoxacin compared with cefoperazone for the treatment of experimental Enterobacter aerogenes endocarditis.In vitro activities of enoxacin, ticarcillin plus clavulanic acid, aztreonam, piperacillin, and imipenem and comparison with commonly used antimicrobial agents.In vitro evaluation of A-56619 and A-56620, two new quinolones.Enoxacin compared with vancomycin for the treatment of experimental methicillin-resistant Staphylococcus aureus endocarditis.Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations.A pleiotropic, posttherapy, enoxacin-resistant mutant of Pseudomonas aeruginosa.Enoxacin directly inhibits osteoclastogenesis without inducing apoptosisThe mode of action of quinolones: the paradox in activity of low and high concentrations and activity in the anaerobic environment.Proposed quality control and interpretive criteria for disk diffusion susceptibility testing with enoxacin.A review of the antimicrobial activity of the fluoroquinolones.Treatment of uncomplicated urogenital gonorrhoea in women with a single dose of enoxacin.Characterization of the porins of Campylobacter jejuni and Campylobacter coli and implications for antibiotic susceptibilityCiprofloxacin: chemistry, mechanism of action, resistance, antimicrobial spectrum, pharmacokinetics, clinical trials, and adverse reactions.The quinolones: an overview and comparative appraisal of their pharmacokinetics and pharmacodynamics.Fluorinated quinolones. A review of their mode of action, antimicrobial activity, pharmacokinetics and clinical efficacy.Bone penetration of enoxacin in patients with and without osteomyelitis.Interaction of the fluoroquinolone antimicrobial agents ciprofloxacin and enoxacin with liposomesEnoxacin penetration into human prostatic tissue.Comparative in vitro activities of enoxacin (CI-919, AT-2266) and eleven antipseudomonal agents against aminoglycoside-susceptible and -resistant Pseudomonas aeruginosa strains.In vitro activity of WIN 49375 compared with those of other antibiotics in isolates from cancer patientsIn vitro evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.In vitro comparison of A-56619, A-56620, amifloxacin, ciprofloxacin, enoxacin, norfloxacin, and ofloxacin against methicillin-resistant Staphylococcus aureusFactors influencing the in vitro activity of two new aryl-fluoroquinolone antimicrobial agents, difloxacin (A-56619) and A-56620.Comparative activity of the quinolones against anaerobic bacteria isolated at community hospitals.In vitro activities of the quinolone antimicrobial agents A-56619 and A-56620.
P2860
Q24670241-2C86ADAE-B597-4AB5-A5BA-CFF03653434EQ24674802-51F57205-E22E-4CB1-B063-47241CE687F7Q24676018-38F431D5-AF4E-4CD4-944C-18C5B089C6BCQ24678414-C6742115-400E-4BA2-9E33-DE512F2C81FAQ30047670-917192BE-5981-468E-8181-8534E73AD157Q33739836-8516DB5B-F5BA-4A30-AC77-5EE1C9C7EFB4Q34417655-46C85981-75D5-4848-ADA0-19DFF6AF44FFQ35303163-8937EC4B-B33C-4525-9CE0-A3B36C69DFB4Q35319641-64F178D9-6C9F-4F51-9113-CDCEE4B41C39Q35543678-B1E7EDC2-06CC-4C67-888C-4F9ABE19AB70Q35568119-758FE873-2871-48C2-9E3B-928A5E541E27Q35568734-DB53C4BC-B6F9-44D4-A8BE-57825F709607Q35568919-25C5B5A7-40EB-48D3-A3F3-5DC8E6B77301Q35639658-A7387AAA-2B31-4DA4-A60D-35D6A938C4E9Q35640867-20AA4914-0D7D-47C4-A545-AB94D8ACB596Q35643969-C74F715D-BBF6-4707-AC77-21154D9FF41FQ35646255-14E22E16-ED88-400F-A8ED-5FCDA3AFC59AQ35648314-D175166E-964E-44E4-ADB9-2B89DF3F1C79Q35648839-D90953D9-246C-453F-90EB-9064E108E02FQ35760862-8A5C51EB-20C0-4B90-B2FF-F746617E8378Q35836280-DD2AE294-3F7A-43C6-B1D3-8E366582AA7DQ36006859-0B016A57-1222-4CD7-86F6-E982B7656C4FQ36670132-3B27D949-23E5-40CD-8071-CF75BABE3906Q37277357-1A951C67-0697-4F59-A775-833125FF2DB3Q37834318-26BE7BF3-7541-492B-8180-6324B9E4FF4AQ37902783-1453E008-9F1D-4D8A-BFED-82BC07C88031Q38272526-362BD8F0-7B7B-45DF-9B4A-028F720E38E4Q39214819-4445E0F2-30A7-4D2D-B7E2-BB9F50DFE6AAQ39637673-941748B8-84B4-4791-BD31-FA8A6BDACC92Q39730719-2F40D88B-B00E-4A43-992D-99AFB63D5AD6Q39818309-52B4A85C-0137-490B-90BA-E2063D948B08Q39819744-47BAC848-8DB4-4B55-974F-ADCBB4065BACQ39832360-0F570571-C1D7-4A09-A468-88E65DDDF1CFQ39833562-1025F312-3B63-4B54-92D7-40A69203302BQ39833569-16C568FD-2CD0-4B9E-B40E-8ABE108F68FFQ39834358-86D334AE-2053-4D8B-95BF-1761EA3BAEFAQ39834459-C40BC689-037F-4F9A-9F29-334BCE7262C7Q39834684-9CB453C3-3C1E-4780-8450-F699B218F434Q39849761-689309DA-A9BB-4526-B10E-B5F0EBFA01BEQ39850428-09431ED1-E4F9-4B57-B3D0-092D54FD1140
P2860
In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprim
description
1983 nî lūn-bûn
@nan
1983 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1983 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1983年の論文
@ja
1983年論文
@yue
1983年論文
@zh-hant
1983年論文
@zh-hk
1983年論文
@zh-mo
1983年論文
@zh-tw
1983年论文
@wuu
name
In vitro activity of enoxacin, ...... noglycosides, and trimethoprim
@ast
In vitro activity of enoxacin, ...... noglycosides, and trimethoprim
@en
In vitro activity of enoxacin, ...... noglycosides, and trimethoprim
@nl
type
label
In vitro activity of enoxacin, ...... noglycosides, and trimethoprim
@ast
In vitro activity of enoxacin, ...... noglycosides, and trimethoprim
@en
In vitro activity of enoxacin, ...... noglycosides, and trimethoprim
@nl
prefLabel
In vitro activity of enoxacin, ...... noglycosides, and trimethoprim
@ast
In vitro activity of enoxacin, ...... noglycosides, and trimethoprim
@en
In vitro activity of enoxacin, ...... noglycosides, and trimethoprim
@nl
P2860
P356
P1476
In vitro activity of enoxacin, ...... noglycosides, and trimethoprim
@en
P2093
P2860
P304
P356
10.1128/AAC.24.5.754
P407
P577
1983-11-01T00:00:00Z